CA2452172A1 - Methodes et compositions de modulation de l'activation cellulaire et utilisations connexes - Google Patents

Methodes et compositions de modulation de l'activation cellulaire et utilisations connexes Download PDF

Info

Publication number
CA2452172A1
CA2452172A1 CA002452172A CA2452172A CA2452172A1 CA 2452172 A1 CA2452172 A1 CA 2452172A1 CA 002452172 A CA002452172 A CA 002452172A CA 2452172 A CA2452172 A CA 2452172A CA 2452172 A1 CA2452172 A1 CA 2452172A1
Authority
CA
Canada
Prior art keywords
cells
cell
1bbl
monocyte
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002452172A
Other languages
English (en)
Inventor
Tania Watts
Jacob Bukczynski
Tao Wen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002452172A priority Critical patent/CA2452172A1/fr
Publication of CA2452172A1 publication Critical patent/CA2452172A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4614Monocytes; Macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4637Other peptides or polypeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/99Coculture with; Conditioned medium produced by genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002452172A 2004-01-12 2004-01-12 Methodes et compositions de modulation de l'activation cellulaire et utilisations connexes Abandoned CA2452172A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002452172A CA2452172A1 (fr) 2004-01-12 2004-01-12 Methodes et compositions de modulation de l'activation cellulaire et utilisations connexes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002452172A CA2452172A1 (fr) 2004-01-12 2004-01-12 Methodes et compositions de modulation de l'activation cellulaire et utilisations connexes

Publications (1)

Publication Number Publication Date
CA2452172A1 true CA2452172A1 (fr) 2005-07-12

Family

ID=34744363

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002452172A Abandoned CA2452172A1 (fr) 2004-01-12 2004-01-12 Methodes et compositions de modulation de l'activation cellulaire et utilisations connexes

Country Status (1)

Country Link
CA (1) CA2452172A1 (fr)

Similar Documents

Publication Publication Date Title
US20040209363A1 (en) Methods and compositions for modulating T cell activation and uses thereof
JP6943933B2 (ja) 癌を治療するためのキメラ抗原受容体改変t細胞の使用
US20220056116A1 (en) Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer
KR102652827B1 (ko) Cd33 특이적 키메라 항원 수용체
CN107074970B (zh) 特异性针对wt-1的t细胞免疫疗法
JP2022091750A (ja) 細胞に基づくネオ抗原ワクチンおよびその使用
EP2817330B1 (fr) Utilisation de récepteurs d'antigène chimériques (car) comportant un costimulateur inductible (icos) afin d'améliorer l'activité antitumorale et la persistance des car
JP5060134B2 (ja) ヒト細胞傷害性Tリンパ球のエピトープ及びそのMUC−1の非VNTR(non−variablenumberoftandemrepeatsequence)由来のアゴニストエピトープ
KR20210043562A (ko) Ror-1 특이적 키메라 항원 수용체 및 그의 용도
JP2015532589A (ja) 投与に関する形質導入t細胞の適合性の評価方法
KR20180104146A (ko) 조작된 항원 제시 세포 및 이의 용도
JP2024059867A (ja) ホスホリパーゼa2受容体キメラ自己受容体t細胞の組成物および方法
AU2024201649A1 (en) A fully-human T cell receptor specific for the 369-377 epitope derived from the HER2/Neu (ERBB2) receptor protein
KR20210021493A (ko) Muc16 특이적 키메라 항원 수용체 및 그의 용도
JP2021526795A (ja) 筋特異的キナーゼキメラ自己受容体細胞の組成物および方法
AU2019310855A2 (en) Method for treating tumor using immune effector cell
JP2022533092A (ja) アセチルコリン受容体キメラ自己抗体受容体細胞の組成物および方法
US20220168347A1 (en) T cell receptors and methods of use thereof
CA3132434A1 (fr) Recepteurs de lymphocytes t et leurs procedes d'utilisation
CA2452172A1 (fr) Methodes et compositions de modulation de l'activation cellulaire et utilisations connexes
RU2795198C2 (ru) Специфичные к muc16 химерные антигенные рецепторы и их применения
US20220168346A1 (en) T cell receptors and methods of use thereof
US20220169696A1 (en) T cell receptors and methods of use thereof
WO2023170633A1 (fr) Utilisation de cellules modifiées d'origine leucémique et d'anticorps pd-l1 pour améliorer l'efficacité d'une thérapie cellulaire dirigée contre le cancer
CA3132238A1 (fr) Recepteurs de lymphocytes t et leurs procedes d'utilisation

Legal Events

Date Code Title Description
FZDE Discontinued